Antara News

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration ...